Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006

Keizo Yamaguchi, Yoshikazu Ishii, Morihiro Iwata, Naoki Watanabe, Nobuyuki Uehara, Minoru Yasujima, Takeshi Kasai, Akira Suwabe, Kumiko Yamahata, Mitsuo Kaku, Keiji Kanemitsu, Yuji Imafuku, Kyouko Nishiyama, Masami Murakami, Sachie Yomoda, Nobuyuki Taniguchi, Toshiyuki Yamada, Fumio Nomura, Masaharu Watanabe, Harushige KannoMasanori Aihara, Shigefumi Maesaki, Giichi Hashikita, Shigemi Kondo, Shigeki Misawa, Hajime Horiuchi, Yoko Tazawa, Hideki Nakashima, Hiromu Takemura, Masahiko Okada, Fusako Yamazaki, Toshinobu Horii, Masato Maekawa, Hisashi Baba, Shiomi Ishigo, Naohisa Fujita, Toshiaki Komori, Satoshi Ichiyama, Yoshitsugu Iinuma, Shigetaka Maeda, Kiyoharu Yamanaka, Yoko Murata, Shuji Matsuo, Hisashi Kohno, Shohiro Kinoshita, Jun Fujita, Kiyoshi Negayama, Mitsuharu Murase, Hitoshi Miyamoto, Nobuchika Kusano, Eiichirou Mihara, Hideyuki Itaha, Junko Ono, Hisae Yoshimura, Katsunori Yanagihara, Junichi Matsuda, Tetsunori Saikawa, Kazufumi Hiramatsu

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 876 strains of Gram-positive bacteria, 1764 strains of Gram-negative bacteria, and 198 strains of anaerobic bacteria obtained from 30 medical institutions during 2006 was measured. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, all of the MEPM-resistant strains were resistant to imipenem (IPM). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (41.8%) and ciprofloxacin-resistant P. aeruginosa (33.3%). 3. The proportion of extended-spectrum β-lactamase (ESBL) strains was 4.3% (6 strains) in Escherichia coli, 1.1% (1 strain) in Citrobacter freundii, 21.7% (5 strains) in Citrobacter koseri, 3.1% (4 strains) in Klebsiella pneumoniae, 3.3% (3 strains) in Enterobacter cloacae, 0.8% (1 strain) in Serratia marcescens, and 4.9% (2 strains) in Providencia spp. The proportion of metallo-β-lactamase strains was 3.1% (10 strains) in P. aeruginosa. 4. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 11 years after available for commercial use.

Original languageEnglish
Pages (from-to)344-377
Number of pages34
JournalJapanese Journal of Antibiotics
Volume60
Issue number6
Publication statusPublished - Dec 2007

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, K., Ishii, Y., Iwata, M., Watanabe, N., Uehara, N., Yasujima, M., Kasai, T., Suwabe, A., Yamahata, K., Kaku, M., Kanemitsu, K., Imafuku, Y., Nishiyama, K., Murakami, M., Yomoda, S., Taniguchi, N., Yamada, T., Nomura, F., Watanabe, M., ... Hiramatsu, K. (2007). Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Japanese Journal of Antibiotics, 60(6), 344-377.